NCT01272245 - Omacetaxine and Low Dose Cytarabine in Older Patients With Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2011

Primary Completion Date

January 31, 2017

Study Completion Date

January 31, 2017

Conditions

Leukemia

Interventions

DRUG

Omacetaxine

1.25 mg/m2 subcutaneously (SQ) every 12 hours (+/- 3 hours) for 3 days (Days 1-3). Each cycle will be 4-7 weeks.

DRUG

Cytarabine

20 mg subcutaneously every 12 hours (+/- 3 hours) for 7 days (Days 1-7). Each cycle will be 4-7 weeks.

Trial Locations (1)

University of Texas MD Anderson Cancer Center, Houston